

Special Issue

Prostate Cancer: Contemporary Standards and Challenges

Message from the Guest Editors

As the second most common cancer among men worldwide and its incidence is rising. In recent decades, researchers have made substantial progress in the molecular characterization, diagnosis, and treatment of this disease, which have greatly improved the outcomes of men with prostate cancer. Breakthroughs in theranostics leveraging the highly prevalent expression of the prostate-specific membrane antigen and improved genetic understanding of the role defects in the homologous recombination pathway play in carcinogenesis have paved the way for truly personalized management.

Recent attempts at intensifying treatment using multiagent combinations have significantly prolonged survival for many patients. However, recognizing the wide variability in clinical behavior of prostate cancer, concerns remain about overtreating some with more indolent, hormone-responsive disease.

In this Special Issue, we aim to provide a comprehensive, multidisciplinary, and contemporary perspective on current standards and challenges in the management of prostate cancer.

To this end, we welcome original research, as well as comprehensive reviews from experts and researchers in the field.

Guest Editors

Dr. Filip Ionescu
Moffitt Cancer Center, Tampa, FL, USA

Dr. Jingsong Zhang
Moffitt Cancer Center, Tampa, FL, USA

Deadline for manuscript submissions

23 October 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/227496

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)